Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
SAN MATEO, Calif., Oct. 7 /PRNewswire-FirstCall/ — Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that Michael R. Bristow, M.D. Ph.D. has joined the Scientific Advisory Board overseeing the development of CD-NP, a dual natriuretic peptide receptor agonist in development for the treatment of acute decompensated heart failure.
Dr. Bristow, a recognized leader in the heart failure community, is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was a founder of ARCA biopharma, a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. Dr. Bristow currently serves as Director, President and Chief Executive Officer of ARCA biopharma. Dr. Bristow was the principal founder of Myogen, biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for the treatment of cardiovascular and pulmonary disease. Dr. Bristow served as Myogen’s Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006. Dr. Bristow is also a founder of Miragen Therapeutics, a Boulder, CO based microRNA company.
“We are extremely pleased to welcome Dr. Bristow to our advisory board,” said Joshua A. Kazam, Nile’s CEO. “We believe that his depth of knowledge in the field of heart failure and his breadth of experience in drug development and commercialization will help us achieve the full potential of CD-NP and our natriuretic peptide program.”
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel, rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a second novel, rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.
Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial and data analysis timelines, anticipated benefits of CD-NP, Nile’s strategy, future operations, outlook, milestones, the timing and success of Nile’s product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile’s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile’s need to raise additional capital to fund its product development programs to completion, Nile’s reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption “Risk Factors” in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 3, 2010. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
SOURCE Nile Therapeutics, Inc.